We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Single Automated Analyzer to Bring Full Suite of Diagnostics to Wherever Patients Are

By HospiMedica International staff writers
Posted on 04 May 2023
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)

Timely and accurate diagnostics can enhance patient care by making it more informed, personalized, and proactive. Now, a novel platform that delivers swift results using minimal blood volumes incorporates technology that facilitates automation and adaptable form factors outside centralized labs, bridging the gap between diagnostics and treatment.

Vital Biosciences Inc. (Mississauga, ON, Canada) is developing a single automated device designed to provide a comprehensive range of diagnostics directly to patients. The company's technology strives to make healthcare significantly more personalized, proactive, and accessible. With only 600 uL of blood, the platform can measure 50+ of the most commonly requested biomarkers in primary care within 20 minutes, without compromising analytical performance. The instrument employs an automated microfluidic workflow to simultaneously run three subsystems: hematology, clinical chemistry, and immunoassays. The platform quantifies the complete panel of biomarkers using on-board optical readers and automated sample preparation and measurement procedures that require minimal user input. This makes the platform suitable for use in CLIA-waived settings.

Vital's initial menu caters to a broad range of potential use cases for the general population, including inflammation, cardiac markers, diabetes, liver disorders, lipid disorders, post-acute event monitoring, clinical trial monitoring, chronic disease management, and proactive lifestyle management. The company aims to create a comprehensive menu that covers 100% of the tests needed for at least 90% of patients, thereby eliminating the need to send tests to a centralized lab. Patients would no longer need to travel to a draw site or ship their samples to a centralized laboratory, nor wait for days to discuss their results with their healthcare provider. Patients who are likely to require bloodwork can provide their sample at check-in and receive results during their initial appointment. Bridging this care gap will make diagnostics more accessible and accelerate clinical decision-making.

Related Links:
Vital Biosciences Inc. 

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Wound Irrigation Solution
Prontosan®

Channels

Surgical Techniques

view channel
Image: The figure shows a photo of the team’s spheroids taken using immunofluorescence imaging, a type of microscopy that allows biologists to view specific proteins or molecules inside a cell or tissue. A total of 16 spheroids, although some are not visible in the figure, are positioned in a microgel structure using a specialized form of 3D printing. In their work, a team of researchers demonstrated that these spheroids can help support the formation of new blood vessels in regenerated bone tissue. (Photo courtesy of Ibrahim Ozbolat/Daniel Hayes)

3D Bioprinting Method Enhances Bone Repair by Promoting Blood Vessel Growth

Severe bone loss after trauma, cancer, or infection is difficult to reconstruct because engineered grafts often fail to form stable blood vessels. Poor vascularization limits nutrient delivery, slows healing,... Read more